» Articles » PMID: 19691089

Bayesian Statistics in Oncology: a Guide for the Clinical Investigator

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2009 Aug 20
PMID 19691089
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The rise of evidence-based medicine as well as important progress in statistical methods and computational power have led to a second birth of the >200-year-old Bayesian framework. The use of Bayesian techniques, in particular in the design and interpretation of clinical trials, offers several substantial advantages over the classical statistical approach. First, in contrast to classical statistics, Bayesian analysis allows a direct statement regarding the probability that a treatment was beneficial. Second, Bayesian statistics allow the researcher to incorporate any prior information in the analysis of the experimental results. Third, Bayesian methods can efficiently handle complex statistical models, which are suited for advanced clinical trial designs. Finally, Bayesian statistics encourage a thorough consideration and presentation of the assumptions underlying an analysis, which enables the reader to fully appraise the authors' conclusions. Both Bayesian and classical statistics have their respective strengths and limitations and should be viewed as being complementary to each other; we do not attempt to make a head-to-head comparison, as this is beyond the scope of the present review. Rather, the objective of the present article is to provide a nonmathematical, reader-friendly overview of the current practice of Bayesian statistics coupled with numerous intuitive examples from the field of oncology. It is hoped that this educational review will be a useful resource to the oncologist and result in a better understanding of the scope, strengths, and limitations of the Bayesian approach.

Citing Articles

Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology.

Sherry A, Msaouel P, Kupferman G, Lin T, Abi Jaoude J, Kouzy R JCO Precis Oncol. 2024; 8:e2400363.

PMID: 39348660 PMC: 11444522. DOI: 10.1200/PO.24.00363.


Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.

Braud A, Auloge P, Meyer N, Bouvrais C, Gharbi M, Lang H Cardiovasc Intervent Radiol. 2024; 47(5):567-572.

PMID: 38570342 DOI: 10.1007/s00270-024-03699-9.


Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials.

Lin T, Sherry A, Ludmir E Semin Radiat Oncol. 2023; 33(4):429-437.

PMID: 37684072 PMC: 10917127. DOI: 10.1016/j.semradonc.2023.06.007.


Implementation of an enhanced recovery program for complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a referral center: a case control prospective study.

Charleux-Muller D, Fabacher T, Romain B, Meyer N, Brigand C, Delhorme J Pleura Peritoneum. 2023; 8(1):11-18.

PMID: 37020473 PMC: 10067553. DOI: 10.1515/pp-2022-0133.


Determinants of the evolutions of behaviours, school adjustment and quality of life in autistic children in an adapted school setting: an exploratory study with the International Classification of Functioning, disability and health (ICF).

Schneider S, Clement C, Goltzene M, Meyer N, Gras-Vincendon A, Schroder C BMC Psychiatry. 2022; 22(1):323.

PMID: 35524241 PMC: 9074195. DOI: 10.1186/s12888-022-03924-0.